Fulcrum Therapeutics, Inc.·4

Jan 30, 9:05 PM ET

Musso Alan A 4

4 · Fulcrum Therapeutics, Inc. · Filed Jan 30, 2024

Insider Transaction Report

Form 4
Period: 2024-01-26
Musso Alan A
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2024-01-26+100,000100,000 total
    Exercise: $6.95Exp: 2034-01-25Common Stock (100,000 underlying)
Footnotes (1)
  • [F1]This option was granted on January 26, 2024 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4